|Printable version||E-mail this to a friend|
EMA Workshop: working towards new therapies for spinal muscular atrophy
The event will be broadcast live on 11 November
The European Medicines Agency (EMA), Spinal muscular atrophy (SMA) Europe and the TREAT-Neuromuscular diseases (NMD) network are holding a one-day workshop to discuss, support and advance the development of therapies for the treatment of spinal muscular atrophy (SMA). SMA Europe and TREAT-NMD network are two non-profit organisations that bring together patients and academics from Europe and beyond to progress research into SMA and facilitate the development of new therapies.
The workshop will take place at EMA’s premises in London on 11 November 2016, starting at 09:00.
SMA is a rare genetic disease that affects the control of muscle movement. It is caused by a loss of specialised nerve cells, called motor neurons, which results in weakness and wasting (atrophy) of muscles used for activities such as crawling, walking, sitting up, and controlling head movement. Children born with the most serious form of the disease rarely survive beyond the age of two because of severe breathing problems.
At present there is no cure for SMA. Available treatments focus on managing symptoms and preventing complications. However, new therapies are currently being developed and SMA might become one of the first inherited neurological diseases to be successfully treated. A number of experimental therapies are currently being evaluated in early clinical trials and EMA has provided scientific advice to medicine developers on the appropriate tests and studies to be used in the development of medicines for SMA a number of times in the past few years.
The workshop will convene key stakeholders – patients, doctors, industry representatives, researchers and regulators – to take stock of the latest scientific developments in the area and discuss ways of developing therapies for the treatment of SMA. Topics for discussion will include an overview of the disease, the pharmacology of the molecules under investigation, natural history data, clinical outcome measures and potential use of biomarkers in drug development.
- Agenda - EMA - Spinal muscular atrophy workshop (07/11/2016)
Latest News from
Disaster resilience - CoR mobilises to turn global commitments into local action28/03/2017 14:25:00
The European Committee of the Regions (CoR), EC and the United Nations Office for Disaster Risk Reduction (UNISDR) seek to accelerate the implementation and monitoring of the Sendai Framework at the European Forum for Disaster Risk Reduction in Istanbul, in order to reduce the impact of natural disasters.
ESMA discusses haircuts in EU securities financing transactions28/03/2017 13:25:00
The European Securities and Markets Authority (ESMA) issued a research piece on shadow banking published in its recent report on trends, risks and vulnerabilities (TRV).
EC gives a boost to youth mobility in Europe28/03/2017 12:25:00
The EC has presented an initiative under the Erasmus+ programme which further supports learning and mobility of young Europeans.
Mergers: EC clears merger between Dow and DuPont, subject to conditions28/03/2017 11:25:00
The EC has approved under the EU Merger Regulation the proposed merger between US-based chemical companies Dow and DuPont. The approval is conditional in particular on the divestiture of major parts of DuPont's global pesticide business, including its global R&D organisation.
MEPs vote to close loopholes for exploiting EU and third country tax differences28/03/2017 10:25:00
Economic and Monetary Affairs Committee MEPs have voted to close loopholes which allow some of the world’s largest corporations to avoid paying tax on profits by exploiting differences in the tax systems of EU and third countries.